May 03, 2021 02:46 PM IST

Remdesivir supply issues might ease by third week of May: Biocon's Kiran Mazumdar-Shaw

The sharp surge in COVID-19 cases across has created a massive demand and consequent shortage of medical oxygen and essential drugs.

Laurus Labs: Diversification to speed up in FY23; add on declines

There is a perceptible change in the Laurus Labs' management commentary in the last 18 months that points to growth sustenance for the medium term

Biocon Consolidated March 2021 Net Sales at Rs 1,838.70 crore, up 16.3% Y-o-Y

Biocon Standalone March 2021 Net Sales at Rs 491.60 crore, up 1.91% Y-o-Y

We will have an abundant supply of Remdesivir by the second week of May: Biocon chief Kiran Mazumdar Shaw

Biocon Executive Chairperson Kiran Mazumdar Shaw says scarcity of critical anti-COVID-19 drugs Remdesivir and Itolizumab will end in 4-6 weeks as suppliers like her own company ramp up output that fell when the pandemic was receding. She said market pricing of vaccines is a must for the much-needed acceleration in inoculation.

Goldman Sachs Private Equity emerges frontrunner to acquire ChrysCap stake in GVK Biosciences

The CRAMs ( contract research and manufacturing services) segment is fetching rich valuations globally and back home, the segment has seen minority stake sale deals like True North-Anthem Biosciences & TPG-Sai Lifesciences.

Biocon Q4 PAT seen up 54.1% YoY to Rs. 203.4 cr: Sharekhan

Net Sales are expected to increase by 28.3 percent Y-o-Y (up 8 percent Q-o-Q) to Rs. 1,999.6 crore, according to Sharekhan.

Biocon's arm gets GMP compliance certificate from UK's health regulator MHRA for Bengaluru facility

"Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom (UK), for its manufacturing facility at Biocon Park in Bengaluru," Biocon said in a regulatory filing.

What ‘second wave’ means for investors in Indian pharma

Multi-year opportunity awaits Indian vaccine manufacturers such as DRL, Gland Pharma, Aurobindo Pharma and Cadila Pharma

Biocon Biologics, Viatris receive EC approval for biosimilar insulin aspart Kixelle

This follows the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, a Biocon statement said on Friday.

Neutral Biocon; target of Rs 385: Motilal Oswal

Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 385 in its research report dated January 22, 2021.

Buy Biocon; target of Rs 470: Sharekhan

Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 470 in its research report dated January 22, 2021.

Hold Biocon; target of Rs 450: ICICI Direct

ICICI Direct recommended hold rating on Biocon with a target price of Rs 450 in its research report dated January 22, 2021.

Biocon may further defer biologics business IPO, says Kiran Mazumdar Shaw

Biocon’s revenue from the biologics business in Q3FY21 was Rs 769 Crore, a 11 percent increase year-on-year and 14 percent rise quarter-on-quarter, Biocon said in a BSE filing.

Biocon share price falls 2% after CLSA retains sell on stock

CLSA has retained sell on the stock and has cut target to Rs 240 from Rs 260 per share

Biocon Q3 net profit falls 19% to Rs 186.6 crore

Expenses rose to Rs 1,642.6 crore for the December quarter, an increase of 14.52 percent, as against Rs 1,434.3 crore in the year-ago period.

Biocon Consolidated December 2020 Net Sales at Rs 1,851.00 crore, up 5.89% Y-o-Y

Biocon Standalone December 2020 Net Sales at Rs 456.10 crore, down 9.02% Y-o-Y

Biocon share price falls 9% after Q3 profit dips 18% YoY to Rs 186 crore

The generics business reported a 3 percent dip in the third quarter at Rs 561 crore, as against Rs 576 crore in the corresponding period last year.

Biocon Q3 PAT may dip 1.5% YoY to Rs. 199.7 cr: ICICI Direct

Net Sales are expected to increase by 15.4 percent Y-o-Y (up 15.7 percent Q-o-Q) to Rs. 2,018.1 crore, according to ICICI Direct.

Biocon shares up 2% after ADQ pumps Rs 555 crore in subsidiary

The transaction is subject to customary condition precedents and approvals. Post the completion of this transaction, Biocon Ltd will hold 89.89 percent stake in Biocon Biologics on a fully diluted basis, the company said.

Sovereign wealth fund ADQ to invest $75 million in Biocon Biologics, deal values firm at around $4 billion

The current investment has put the post-money valuation of Biocon Biologics at ~$4.17 billion, said Kiran Mazumdar-Shaw, Executive Chairperson of Biocon

Buy Biocon: target of Rs 520: Sharekhan

Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 520 in its research report dated December 28, 2020.

Biocon share price rises 2% on launch of Tacrolimus capsules in US

The share touched its 52-week high Rs 487.70 and 52-week low Rs 235.80 on 23 December, 2020 and 19 March, 2020, respectively.

Biocon share price slips after CLSA retains 'sell' call, expects stock to dip to Rs 250

Biocon Biologics, and Mylan have been informed by the US health regulator of deferred action on the biologics licence application for a biosimilar to drug Avastin, used to treat various types of cancers, Biocon said.